Obesity · 2007 · 55 citations · 25 references
The PEM studies highlighted different adverse event profiles for orlistat and sibutramine that were consistent with their distinct pharmacological mechanisms and other published information.
25
David W. Haslam, W. P. T. James · The Lancet · 2005 · 3.8K citations
In Defense of Case Reports and Case Series
Jan P. Vandenbroucke · Annals of Internal Medicine · 2001 · 541 citations
Surveying general practitioners: does a low response rate matter?
L Templeton, Ann Deehan, Celia Taylor et al. · PubMed · 1997 · 229 citations · Full text